escitalopram oxalate · Abbvie · NDA 021323, 021365
Lexapro
Earliest generic entry, as listed · earliest of 3 marketed strengths
Open now
No unexpired patents or exclusivities are listed for this product.
Listed patents · 0 unexpired
No unexpired patents listed.
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
- Generic approved · ANDA 091655, Micro Labs · 021323-001Approved 22 Apr 2026Detected 25 Oct 2026Historical import
Products covered · 4
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 021323 · 001 · RLD | tablet, oral | EQ 5MG BASE | open |
| 021323 · 002 · RLD | tablet, oral | EQ 10MG BASE | open |
| 021323 · 003 · RLD | tablet, oral | EQ 20MG BASE | open |
| 021365 · 001 · RLD · discontinued | solution, oral | EQ 5MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | open |
Expired or delisted (1)
- NPP · 12 May 2026